Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2017

01-03-2017 | Letter to the Editor

Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center

Authors: Karla Javier González, Sebastian Ortiz Zuluaga, Carolina Villegas DaRos, Pedro Pérez Rodríguez, Antonio Cerveró Martí

Published in: Annals of Hematology | Issue 3/2017

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Mazza P, Minoia C, Melpignano A (2016) The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol 95(2):239–244. doi:10.​1007/​s00277-015-2556-z CrossRefPubMed
2.
Kuter D, Bussel J, Lyons R (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet 371:395–403CrossRefPubMed
3.
Bussel J, Provan D, Shamsi T (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomized, double-blind, placebo-controlled trial. Lancet 373:641–648CrossRefPubMed
4.
Rodeghiero F, Stasi R, Gernsheimer T (2009) Standarization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386–2393. doi:10.​1182/​blood-2008-07-162503 CrossRefPubMed
5.
González-Porras J, Mingot-Castellano M, Andrade M (2014) Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol. doi:10.​1111/​bjh.​13266
6.
Aoki T, Harada Y, Matsubara E (2012) Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Ther. doi:10.​1111/​j.​1365-2710-2012-01353.​x
7.
Polverelli N, Palandri F, Iaocobucci I (2013) Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms. Br J Haematol 161:136–153CrossRef
8.
D´Arena G, Guariglia R, Mansueto G (2013) No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic pupura. Blood 121(7):1240–1241CrossRef
9.
Tsukamoto S, Nakaseko C, Takeuchi M (2013) Safety and efficacy of romiplostim in patients with eltrombopag-resistant or intolerant immune thrombocytopenia. Br J Haematol 163:277–291PubMed
10.
Khellaf M, Viallard JF, Hamidou M (2013) A retrospective pilot evaluation of switching thrompoietic receptor-agonists in immune thrombocytopenia. Haematologica 98(6):881–887CrossRefPubMedPubMedCentral
Metadata
Title
Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center
Authors
Karla Javier González
Sebastian Ortiz Zuluaga
Carolina Villegas DaRos
Pedro Pérez Rodríguez
Antonio Cerveró Martí
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 3/2017
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2896-3

Other articles of this Issue 3/2017

Annals of Hematology 3/2017 Go to the issue

Letter to the Editor

Intravascular lymphoma: look through the small vessels

Original Article

Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone

Letter to the Editor

Potential value of FDG PET-CT in diagnosis and follow-up of TAFRO syndrome

Original Article

Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN

Original Article

Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause

Letter to the Editor

Evidence for a role of decitabine in the treatment of myeloid sarcoma

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits